anti-SARS-CoV-2 program (Xlife Sciences AG)

N/A

Report date: 2025/01/26 19:31:56
NME

Base Information

Drug Nameanti-SARS-CoV-2 program (Xlife Sciences AG)
Drug Alias Nameundisclosed therapy (Xlife sciences)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVirus replication inhibitors
TargetsUpdating
Therapy Area/IndicationsCoronavirus InfectionsInfluenza, Human
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesXlife Sciences AG
China Registration ClassN/A

Develop Information

Active CompaniesXlife Sciences AG
Inactive CompaniesN/A
Active IndicationsCoronavirus InfectionsInfluenza, Human
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A